Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen

Journal of Chemotherapy

Volumn 24, Issue 4, 2012, Pages 245-246

  Tenti, Sara ^a   Correale, Pierpaolo ^a   Conca, Raffaele ^a   Pastina, Pierpaolo ^a   Fioravanti, Antonella ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ARTIFICIAL TEAR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LEVOLEUCOVORIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN;

AGED; ARTHRALGIA; CANCER PATIENT; CANCER SURVIVOR; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; JOINT STIFFNESS; KERATOCONJUNCTIVITIS SICCA; LETTER; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; PARESTHESIA; RECTUM CARCINOMA; SALIVARY GLAND BIOPSY; SCHIRMER TEST; SJOEGREN SYNDROME; XEROPHTHALMIA; XEROSTOMIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, METRONOMIC; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; COLONIC NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LEUCOVORIN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAINTENANCE CHEMOTHERAPY; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84866264244     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000008     Document Type: Letter

References (7)

1. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008;14:4192-9.
2. Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother. 2008;20:278-81.
3. Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, et al. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer. 2004;90:1710-4.
4. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologie and anti-tumor activity in metastatic colon cancer patients. J Clin Oncol. 2005;23:8950-8.
5. Fox RI. Sjögren's syndrome. Lancet. 2005;366:321-31.
6. Li X, Li X, Qian L, Wang G, Zhang H, Wang X, et al. T regulatory cells are markedly diminished in diseased salivary glands of patients with primary Sjögren's syndrome. J Rheumatol. 2007;34:2438-45.
7. Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, et al. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother. 2008;20:119-25.